此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

SpaceOAR Vue 系统在接受立体定向放射治疗的前列腺癌患者中的有效性 (SABRE)

2026年11月10日 更新者:Boston Scientific Corporation

To demonstrate the effectiveness of the SpaceOAR Vue System in reducing late gastrointestinal (GI) toxicity in subjects undergoing Stereotactic Body Radiotherapy (SBRT) to treat prostate cancer.

研究概览

地位

主动,不招人

条件

详细说明

This study is designed to evaluate the effectiveness of the SpaceOAR Vue System in reducing late gastrointestinal (GI) toxicity in participants undergoing Stereotactic Body Radiotherapy (SBRT) for the treatment of prostate cancer.

研究类型

介入性

注册 (实际的)

500

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Bonn、德国、D-53129
        • MEDICLIN Robert Janker Klinik
      • Nuremberg、德国、90419
        • Klinikum Nurnberg Nord
      • Parma、意大利、43126
        • Azienda Ospedaliero Universitaria di Parma
      • Rome、意大利
        • Policlinico Universitario Agostino Gemelli
      • Verona、意大利、37024
        • IRCCS Ospedale Sacro Cuore Don Calabria
      • Levallois-Perret、法国、92300
        • Institut de Radiothérapie & Radiochirurgie HARTMANN
    • Cedex
      • Villejuif、Cedex、法国、94805
        • Institut Gustave Roussy
    • New South Wales
      • Waratah、New South Wales、澳大利亚、2298
        • Calvary Mater Newcastle
    • Queensland
      • Woolloongabba、Queensland、澳大利亚、4102
        • Princess Alexandra Hospital - ROPAIR
    • Western Australia
      • Nedlands、Western Australia、澳大利亚、6009
        • Sir Charles Gairdner Hospital
      • Cork、爱尔兰、T12 DV56
        • Bon Secours Radiotherapy Cork
      • Basel、瑞士、CH-4031
        • University Hospital Basel
      • Bern、瑞士、3010
        • Inselspital - University Hospital Bern
    • Florida
      • Fort Myers、Florida、美国、33908
        • GenesisCare USA
      • Tampa、Florida、美国、33609
        • Florida Urology Partners, LLC
    • Kansas
      • Kansas City、Kansas、美国、66160
        • Kansas University Medical Center
    • Michigan
      • Troy、Michigan、美国、48098
        • GenesisCare USA
    • New Jersey
      • Bloomfield、New Jersey、美国、07003
        • New Jersey Urology, a Summit Health Company
    • Pennsylvania
      • Pittsburgh、Pennsylvania、美国、15232
        • University of Pittsburgh Medical Center
    • South Carolina
      • Myrtle Beach、South Carolina、美国、29572
        • Dr. John Sylvester
      • Belfast、英国、BT9 7AB
        • Belfast City Hospital
      • Bristol、英国、BS2 8ED
        • Bristol Haematology and Oncology Centre
      • London、英国、SW3 6JJ
        • Royal Marsden Hospital
      • Norwich、英国、NR4 7UY
        • Norfolk and Norwich University Hospital NHS Trust
      • Plymouth、英国、PL6 8DH
        • Derriford General Hospital
    • Surrey
      • Guildford、Surrey、英国、GU27XX
        • Royal Surrey County Hospital NHS Foundation Trust
    • Wales
      • Cardiff、Wales、英国、CF14 2TL
        • Velindre Cancer Centre
      • Barakaldo、西班牙、48903
        • Hospital Universitario Cruces
      • Madrid、西班牙、28002
        • GenesisCare, Hospital San Francisco de Asis
      • Madrid、西班牙
        • Hospital Universitario Ramón y Cajal

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

男性

描述

Inclusion Criteria:

  • Age ≥ 18 years old.
  • Subjects must have pathologically confirmed (by routine hematoxylin and eosin (H&E) staining) invasive adenocarcinoma of the prostate and been planning to undergo SBRT.
  • Subjects must have intermediate risk prostate cancer as defined by the presence of one or more of the following:
  • Clinical Stage T2b - T2c (AJCC 6th edition) tumor
  • Gleason Score 7 as determined from a biopsy taken within 9 months preceding Enrollment (randomization)
  • Demonstrated blood PSA levels 10-20 ng/ml as measured within 6 months preceding Enrollment (randomization) and prior to commencing androgen deprivation therapy (ADT)
  • Subject or authorized representative was informed of the nature of the study and provided written informed consent, approved by the appropriate Institutional Review Board (IRB)/Ethics Committee (EC) of the respective clinical site.

Exclusion Criteria:

  • Prostate >80 cc documented within 9 months preceding Enrollment (randomization)
  • Clinical stage T3 or T4 (AJCC 6th edition) tumor
  • Blood PSA level >20 ng/ml as measured within 6 months preceding Enrollment (randomization) and prior to commencing androgen deprivation therapy (ADT)
  • Gleason Score ≥ 8 as determined from a biopsy taken within 9 months preceding Enrollment (randomization)
  • Subjects who had MRI evidence of gross posterior extracapsular extension (ECE) of the prostate cancer. (Note: MRI should be from within 9 months preceding Enrollment (randomization). If MRI is contraindicated, a digital rectal exam may be performed to confirm the absence of gross posterior ECE)
  • Subjects who had metastatic disease, other ongoing cancers which were treated during the study or subjects for whom pelvic lymph node radiotherapy was planned.
  • Subjects with any prior invasive malignancy (except non-melanomatous skin cancer) unless the subject had been disease free for a minimum of 3 years.
  • History of prostatectomy, transurethral prostate surgery (e.g. TUNA, TUMT, TURP) if performed within 1 year prior to screening, other local prostate cancer therapy (e.g., cryotherapy or brachytherapy) or previous pelvic irradiation at any time prior to screening.
  • History of prior pelvic surgery requiring low anterior or abdominoperineal resections or rectal surgery.
  • History of or active inflammatory bowel disease (IBD) such as Crohn's disease or ulcerative colitis.
  • History of or current perirectal disease that may interfere with interpretation of study outcomes including anal or perianal diseases such as fistula.
  • Bleeding hemorrhoids requiring medical intervention within the prior three months.
  • Diagnosed active bleeding disorder or a clinically significant coagulopathy. Note: Patients on anticoagulants may be included if the anticoagulant medication can be discontinued for index procedure.
  • Active inflammatory or infectious process involving the perineum, gastrointestinal (GI) or urinary tract based on positive diagnosis or suspected diagnosis in the presence of fever >38⁰ C, WBC > 12,000/uL.
  • Compromised immune system or prior diagnoses for human immunodeficiency virus (HIV) (with a detectable viral load within the last 6 months)/acquired immunodeficiency syndrome (AIDS) or autoimmune disease.
  • If a subject was enrolled in another investigational drug or device trial that had not completed the primary endpoint or that clinically interfered with this study.
  • Unable to comply with the study requirements or follow-up schedule.
  • Any condition the Investigator believed would interfere with the intent of the study or would make participation not in the best interest of the patient.
  • Known iodine sensitivity or allergy
  • Known polyethylene glycol (PEG) sensitivity or allergy

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
无干预:No-Spacer Control

Subjects will receive radiotherapy without the use of the SpaceOAR Vue.

实验性的:SpaceOAR Vue

Subjects will receive radiotherapy following injection of the SpaceOAR Vue hydrogel.

The SpaceOAR Vue System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of the SpaceOAR Vue System to reduce the radiation dose delivered to the anterior rectum.

The SpaceOAR Vue System is composed of biodegradable material, maintains space for the entire course of prostate radiotherapy treatment and is completely absorbed by the patient's body over time.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Late Gastrointestinal (GI) Toxicity
大体时间:3 to 24 months post-SBRT initiation

Proportion of subjects experiencing late GI toxicity after SBRT treatment with or without placement of the SpaceOAR Vue System hydrogel. Late GI toxicity is defined as the occurrence of a Grade 2 or greater GI adverse event (NCI CTCAE v4) between 3- and 24-months post-SBRT initiation

3 to 24 months post-SBRT initiation

次要结果测量

结果测量
措施说明
大体时间
EPIC-26 bowel score
大体时间:24 months post-SBRT initiation

Proportion of subjects experiencing a decrease in EPIC-26 bowel score greater than or equal to the minimal important difference (MID) in EPIC-26 bowel score from baseline to 24 months post-SBRT initiation.

24 months post-SBRT initiation

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Suneil Jain, MB, BCh, PhD、Queen's University, Belfast

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2021年12月21日

初级完成 (估计的)

2027年12月1日

研究完成 (估计的)

2030年12月1日

研究注册日期

首次提交

2021年5月24日

首先提交符合 QC 标准的

2021年5月24日

首次发布 (实际的)

2021年5月27日

研究记录更新

最后更新发布 (实际的)

2026年11月12日

上次提交的符合 QC 标准的更新

2026年11月10日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

是的

在美国制造并从美国出口的产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅